Literature DB >> 26763410

Early deaths in bloodstream infections: a population-based case series.

Keiju S K Kontula1, Kirsi Skogberg1, Jukka Ollgren2, Asko Järvinen1, Outi Lyytikäinen2.   

Abstract

A notable portion of deaths in bloodstream infections (BSI) have previously been shown to occur within 2 days after taking the first positive blood culture specimen. The aim of this study was to analyse patients' characteristics and causative pathogens of BSIs, leading to early deaths in order to explore possibilities for prevention. Patients with BSI in Helsinki and Uusimaa region (population = 1.5 million) in 2007 were identified from the National Infectious Disease Register (n = 2181) and their deaths within 2 days after the first positive blood culture from the Population Information System (n = 76). Of the early fatal BSIs, 42 (55%) were community-acquired (CA-BSI) and 34 (45%) healthcare-associated (HA-BSI). Charlson comorbidity index was moderate-to-high (index ≥ 3) in 71% of HA-BSIs and 60% of CA-BSIs. The most common pathogens in CA-BSIs were Streptococcus pneumoniae (29%) and Escherichia coli (24%) and in HA-BSIs Pseudomonas aeruginosa (24%) and Staphylococcus aureus (18%). The respiratory tract (50%) was the most common focus of infection. Empiric antimicrobial treatment was more often appropriate in CA-BSIs vs HA-BSIs (81% vs 41%, p < 0.001), but treatment delays were longer in CA-BSIs. The majority of the BSI patients who died early had severe comorbidities. S. pneumoniae accounted for one third of CA-BSIs, highlighting the potential role of pneumococcal vaccines in prevention. Early recognition of BSI and its origin (CA-BSI vs HA-BSI) is crucial. Continuous surveillance data on causative microbes and resistance trends in hospitals is needed to propose guidelines for empiric antimicrobial therapy of BSIs.

Entities:  

Keywords:  Bloodstream infection; community-acquired; early death; healthcare-associated

Mesh:

Substances:

Year:  2016        PMID: 26763410     DOI: 10.3109/23744235.2015.1131329

Source DB:  PubMed          Journal:  Infect Dis (Lond)        ISSN: 2374-4243


  7 in total

1.  Visualizing Infection Surveillance Data for Policymaking Using Open Source Dashboarding.

Authors:  Monika Maya Wahi; Natasha Dukach
Journal:  Appl Clin Inform       Date:  2019-07-24       Impact factor: 2.342

2.  The outcome and timing of death of 17,767 nosocomial bloodstream infections in acute care hospitals in Finland during 1999-2014.

Authors:  Keiju S K Kontula; Kirsi Skogberg; Jukka Ollgren; Asko Järvinen; Outi Lyytikäinen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-02-17       Impact factor: 3.267

3.  Prevalence and risk factors for bloodstream infection present on hospital admission.

Authors:  Sainfer Aliyu; Bevin Cohen; Jianfang Liu; Elaine Larson
Journal:  J Infect Prev       Date:  2017-07-28

4.  Staphylococcus aureus Bacteremia in Patients Infected With COVID-19: A Case Series.

Authors:  Jaclyn A Cusumano; Amy C Dupper; Yesha Malik; Elizabeth M Gavioli; Jaspreet Banga; Ana Berbel Caban; Devika Nadkarni; Ajay Obla; Chirag V Vasa; Dana Mazo; Deena R Altman
Journal:  Open Forum Infect Dis       Date:  2020-11-12       Impact factor: 3.835

5.  Early deaths associated with community-acquired and healthcare-associated bloodstream infections: a population-based study, Finland, 2004 to 2018.

Authors:  Keiju Sk Kontula; Kirsi Skogberg; Jukka Ollgren; Asko Järvinen; Outi Lyytikäinen
Journal:  Euro Surveill       Date:  2022-09

6.  Early Biomarker-Guided Prediction of Bloodstream Infection in Critically Ill Patients: C-Reactive Protein, Procalcitonin, and Leukocytes.

Authors:  Frederik Boetius Hertz; Magnus G Ahlström; Morten H Bestle; Lars Hein; Thomas Mohr; Jens D Lundgren; Tina Galle; Mads Holmen Andersen; Daniel Murray; Anne Lindhardt; Theis Skovsgaard Itenov; Jens Ulrik Staehr Jensen
Journal:  Open Forum Infect Dis       Date:  2022-09-14       Impact factor: 4.423

7.  Mortality after Delay of Adequate Empiric Antimicrobial Treatment of Bloodstream Infection.

Authors:  Merel M C Lambregts; Roos Wijnakker; Alexandra T Bernards; Leo G Visser; Saskia le Cessie; Mark G J de Boer
Journal:  J Clin Med       Date:  2020-05-07       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.